EUVIMEDEUVIMED entdecken
Crossref

Clinical utility of EBV DNA testing of blood in immunocompetent and immunocompromised patients: A single-center experience

Simran Gupta, Sarah E Turbett iD, Erik Klontz, Camille N Kotton

American Journal of Clinical Pathology · 2025

DOI: 10.1093/ajcp/aqae143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Simran Gupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Transplant and Immunocompromised Host Infectious Diseases, Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School…. Hauptthemen laut MEDLINE: Immunocompromised Host, Epstein-Barr Virus Infections, DNA, Viral, Herpesvirus 4, Human. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Epstein-Barr virus (EBV) causes different clinical presentations in immunocompetent and immunocompromised persons, and thus indications for testing vary between these populations. We reviewed our institution’s EBV DNA testing across these populations to understand its clinical utility and appropriateness.

Methods

We conducted a retrospective chart review of adult patients with positive EBV nucleic acid amplification (NAAT) testing from November 2022 to 2023. We recorded demographics, indications for testing, EBV-related diagnosis, laboratory results, and whether testing influenced patient treatment.

Results

Of 3560 EBV NAAT tests, 187 (5.3%) were positive, representing 124 unique adult patients (51 immunocompetent and 73 immunocompromised). Reactivation of EBV was the most common diagnosis in both populations, followed by acute EBV infection in the immunocompetent and non-posttransplant lymphoproliferative disorder malignancies in the immunocompromised. In immunocompromised patients, positive tests led to treatment changes more frequently than in immunocompetent patients (27.4% vs 11.7%, P = .06). Testing affected clinical management in 0% to 2% of cases when sent for sepsis/shock and nonspecific viral syndromes compared to 37% to 49% of cases when sent for posttransplant and malignancy screening/monitoring.

Discussion

EBV NAAT testing infrequently influenced clinical management in immunocompetent individuals but had a notable impact in immunocompromised patients, particularly those undergoing posttransplant or malignancy screening. This underscores the need for targeted testing to optimize resource utilization and cost-effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunocompromised HostEpstein-Barr Virus InfectionsDNA, ViralHerpesvirus 4, HumanHumansRetrospective StudiesMaleAdultFemaleMiddle AgedAgedYoung AdultNucleic Acid Amplification TechniquesImmunocompetenceAdolescent

Stichwörter der Autor:innen

EBV DNAEBV DNAemiaEBV NAATEBV reactivationPTLDacute EBV infectionimmunocompetentimmunocompromisedlymphoid malignancy

Substanzen

DNA, Viral

Autor:innen und Institutionen

  • Transplant and Immunocompromised Host Infectious Diseases, Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, US.
  • Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, US.

ORCID-Profile: Sarah E Turbett

Zitieren

APA

Gupta, S., Turbett, S. E., Klontz, E., & Kotton, C. N. (2025). Clinical utility of EBV DNA testing of blood in immunocompetent and immunocompromised patients: A single-center experience. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae143

Vancouver

Gupta S, Turbett SE, Klontz E, Kotton CN. Clinical utility of EBV DNA testing of blood in immunocompetent and immunocompromised patients: A single-center experience. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae143

BibTeX
@article{Gupta2025,
  author = {Gupta, Simran and Turbett, Sarah E and Klontz, Erik and Kotton, Camille N},
  title = {Clinical utility of EBV DNA testing of blood in immunocompetent and immunocompromised patients: A single-center experience},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  doi = {10.1093/ajcp/aqae143}
}
Kostenlos starten →